Stock prices of major new drug developing companies increased by 32.8% this year
On September 4, according to the report of Shinhan Investment & Securities, stock prices of major new drug developing companies increased by 32.8% this year.
In case of Genexine whose largest shareholder changed to Handok in March, is recording the highest stock growth rate this year among new d...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
